CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA

被引：0
|
作者：
Gay, F. [1 ]
Scalabrini, D. Rota [2 ]
Belotti, A. [2 ]
Offidani, M. [2 ]
Tacchetti, P. [2 ]
Petrucci, M. T. [2 ]
Pautasso, C. [1 ]
Palmas, A. D. [2 ]
Siniscalchi, A. [2 ]
Grasso, M. [2 ]
Spadano, A. [2 ]
Giuliani, N. [2 ]
Ballanti, S. [2 ]
Patriarca, F. [2 ]
Canepa, L. [2 ]
Bernardini, A. [1 ]
Aquino, S. [2 ]
Gamberi, B. [2 ]
Zambello, R. [2 ]
Ledda, A. [2 ]
Montefusco, V. [2 ]
Omede, P. [1 ]
Galli, M. [2 ]
Cavo, M. [2 ]
Palumbo, A. [1 ,3 ,4 ]
Musto, P. [2 ]
Boccadoro, M. [1 ]
机构：
[1] Univ Torino, Div Hematol, Myeloma Unit, Turin, Italy
[2] Italian Multiple Myeloma Network, Gimema, Italy
[3] Takeda Pharmaceut Co Employee, Turin, Italy
[4] Takeda Pharmaceut Co, Zurigo, Switzerland
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S410
引用
收藏
页码：143 / 144
页数：2
相关论文
共 50 条
  • [31] Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
    M A Dimopoulos
    A K Stewart
    T Masszi
    I Špička
    A Oriol
    R Hájek
    L Rosiñol
    D Siegel
    G G Mihaylov
    V Goranova-Marinova
    P Rajnics
    A Suvorov
    R Niesvizky
    A Jakubowiak
    J San-Miguel
    H Ludwig
    S Ro
    S Aggarwal
    P Moreau
    A Palumbo
    Blood Cancer Journal, 2017, 7 : e554 - e554
  • [32] Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients
    Palumbo, Antonio
    Bringhen, Sara
    Villani, Oreste
    Siniscalchi, Agostina
    Russo, Eleonora
    Uccello, Giuseppina
    Cerrato, Chiara
    Gilestro, Milena
    Rossi, Davide
    Boccadoro, Mario
    BLOOD, 2012, 120 (21)
  • [33] Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies
    Landgren, Ola
    Kazandjian, Dickran
    Roussel, Murielle
    Jasielec, Jagoda
    Dytfeld, Dominik
    Anderson, Aparna
    Kervin, Tara A.
    Iskander, Karim
    McFadden, Ian
    Jakubowiak, Andrzej J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (10) : 2413 - 2421
  • [34] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Korde, Neha
    Derkach, Andriy
    Hultcrantz, Malin
    Maclachlan, Kylee H.
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Lesokhin, Alexander
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Hofmeister, Craig C.
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Usmani, Saad Z.
    Lonial, Sagar
    Joseph, Nisha S.
    BLOOD, 2023, 142
  • [35] Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study
    Landgren, Ola
    Siegel, David S.
    Auclair, Daniel
    Chari, Ajai
    Boedigheimer, Michael
    Welliver, Tim
    Mezzi, Khalid
    Iskander, Karim
    Jakubowiak, Andrzej
    BLOOD, 2018, 132
  • [36] Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
    Onda, Yoshiyuki
    Kanda, Junya
    Kaneko, Hitomi
    Shimura, Yuji
    Fuchida, Shin-ichi
    Nakaya, Aya
    Itou, Tomoki
    Yamamura, Ryosuke
    Tanaka, Hirokazu
    Shibayama, Hirohiko
    Shimazu, Yutaka
    Uchiyama, Hitoji
    Yoshihara, Satoshi
    Adachi, Yoko
    Matsuda, Mitsuhiro
    Hanamoto, Hitoshi
    Uoshima, Nobuhiko
    Kosugi, Satoru
    Ohta, Kensuke
    Yagi, Hideo
    Kanakura, Yuzuru
    Matsumura, Itaru
    Hino, Masayuki
    Nomura, Shosaku
    Shimazaki, Chihiro
    Takaori-Kondo, Akifumi
    Kuroda, Junya
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [37] A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma
    Bringhen, Sara
    Cerrato, Chiara
    Petrucci, Maria Teresa
    Genuardi, Mariella
    Gentilini, Fabiana
    Conticello, Concetta
    Oliva, Stefania
    Pantani, Lucia
    Offidani, Massimo
    Palladino, Carmela
    Benevolo, Giulia
    Montefusco, Vittorio
    Astolfi, Monica
    Villani, Oreste
    Siniscalchi, Agostina
    Rocci, Alberto
    De Paoli, Lorenzo
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    BLOOD, 2013, 122 (21)
  • [38] Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies
    Landgren, Ola
    Attal, Michel
    Kazandjian, Dickran
    Roussel, Murielle
    Jasielec, Jagoda K.
    Dytfeld, Dominik
    Anderson, Aparna
    Kervin, Tara
    Iskander, Karim
    Mezzi, Khalid
    Welliver, Tim
    Yusuf, Akeem
    Jakubowiak, Andrzej
    BLOOD, 2019, 134
  • [39] VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
    Piedra, Katrina M.
    Hassoun, Hani
    Buie, Larry W.
    Devlin, Sean M.
    Flynn, Jessica
    Hultcrantz, Malin
    Lesokhin, Alexander M.
    Lu, Sydney X.
    Mailankody, Sham
    Shah, Urvi A.
    Smith, Eric L.
    Landgren, Ola
    Korde, Neha
    Peterson, Tim J.
    BLOOD, 2019, 134
  • [40] Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
    Derman, Benjamin A.
    Cooperrider, Jennifer
    Rosenblatt, Jacalyn
    Avigan, David E.
    Rampurwala, Murtuza
    Barnidge, David
    Major, Ajay
    Karrison, Theodore
    Jiang, Ken
    Ramsland, Aubrianna
    Kubicki, Tadeusz
    Jakubowiak, Andrzej J.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
12345